Lirametostat - MorphoSys
Alternative Names: CPI-1205Latest Information Update: 01 Aug 2024
Price :
$50 *
At a glance
- Originator Constellation Pharmaceuticals
- Developer MorphoSys
- Class Amides; Antineoplastics; Ethers; Fluorinated hydrocarbons; Indoles; Piperidines; Pyridines; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued B-cell lymphoma; Multiple myeloma; Prostate cancer; Solid tumours
Most Recent Events
- 10 Jun 2021 Discontinued - Phase-I for B-cell lymphoma (Second-line therapy or greater) in USA (PO) (Constellation Pharmaceuticals pipeline, June 2021)
- 10 Jun 2021 Discontinued - Phase-II for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (PO) (Constellation Pharmaceuticals pipeline, June 2021)
- 10 Jun 2021 Discontinued - Preclinical for Multiple myeloma in USA (PO) (Constellation Pharmaceuticals pipeline, June 2021)